

REMARKS

Claims 1-18 were pending. Claims 2-3, and 11-12 are canceled. Claims 1, 4, 6-8, 10 13 and 15-17 are amended. No new matter is added. In view of the following remarks, Applicants respectfully request reconsideration of the rejections.

Claims 4, 6, 7, 8, 13, 15, 16 and 17 have been rejected under 35 U.S.C. 112, second paragraph as lacking antecedent support for the term "said inhibitor". The claims have been amended to recite "compound" and set forth in the base claim. Withdrawal of the rejection is requested.

Claims 1, 4, 5-10 and 13-18 have been rejected under 35 U.S.C. 112, first paragraph. The office action states that the specification is enabling for a method of preventing inflammation in a host *in vitro*, but questions Applicants' enablement of *in vivo* embodiments.

In order to further prosecution, Applicants have amended the currently pending claims to recite the use of an *in vitro* model, without conceding to the correctness of the rejection or relinquishing the right to refile claims of the original scope in a continuing application.

Withdrawal of the rejection is requested.


CONCLUSION

Applicants submit that all of the claims are now in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, she is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number KINE-001CON2.

Respectfully submitted,

Date: Dec. 9, 2003

By: 
Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231